Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia
Eric D. Achtyes, Seth C. Hopkins, Nina Dedic, et al.
European Archives of Psychiatry and Clinical Neuroscience (2023) Vol. 273, Iss. 7, pp. 1543-1556
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives
Antonio Vita, Gabriele Nibbio, Sergio Barlati
Schizophrenia Bulletin Open (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 12
TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding
Nina Dedic, Lien Wang, Éva Hajós‐Korcsok, et al.
Molecular Metabolism (2024) Vol. 80, pp. 101883-101883
Open Access | Times Cited: 8
Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data
Spyridon Siafis, Virginia Chiocchia, Malcolm Macleod, et al.
Wellcome Open Research (2024) Vol. 9, pp. 182-182
Open Access | Times Cited: 8
Treatment Updates in Schizophrenia and Schizophrenia Spectrum Disorders
Nancy Shenoi, Abdulla Alobaidi, Kim-Lan Czelusta, et al.
Psychiatric Annals (2025) Vol. 55, Iss. 1
Closed Access | Times Cited: 1
Novel Compounds in the Treatment of Schizophrenia—A Selective Review
Eva-Maria Tsapakis, Kalliopi Diakaki, Apostolos Miliaras, et al.
Brain Sciences (2023) Vol. 13, Iss. 8, pp. 1193-1193
Open Access | Times Cited: 18
The dark sides of the GPCR tree ‐ research progress on understudied GPCRs
Magdalena M. Scharf, Laura J. Humphrys, Sandra Berndt, et al.
British Journal of Pharmacology (2024)
Open Access | Times Cited: 6
Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular Modeling
Giancarlo Grossi, Naomi Scarano, Francesca Musumeci, et al.
Molecules (2024) Vol. 29, Iss. 8, pp. 1739-1739
Open Access | Times Cited: 6
The New Horizon of Antipsychotics beyond the Classic Dopaminergic Hypothesis—The Case of the Xanomeline–Trospium Combination: A Systematic Review
Octavian Vasiliu, Beatrice Budeanu, Mihai-Ștefan Cătănescu
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 610-610
Open Access | Times Cited: 5
Trace amine signaling in zebrafish models: CNS pharmacology, behavioral regulation and translational relevance
David S. Galstyan, Natalia A. Krotova, A. S. Lebedev, et al.
European Journal of Pharmacology (2025), pp. 177312-177312
Closed Access
Schizophrenia Management: Systematic Review of Current Medications and Phase-3 Agents (2008–2024)
Salma Abdelmoteleb, Jayant Totlani, Salma Ramadan, et al.
Neuroscience Applied (2025) Vol. 4, pp. 105507-105507
Open Access
Novel pharmaceutical treatment approaches for schizophrenia: a systematic literature review
Anan S. Jarab, Walid Al‐Qerem, Adam Khdour, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access
Advancements in Psychiatric Care: DSM-5-TR Revisions and Recent Psychopharmacological Developments
Elizabeth Hutson, Lyons T. Hardy, Erin Ellington, et al.
Journal of Psychosocial Nursing and Mental Health Services (2025), pp. 1-13
Closed Access
New pharmacological approaches in the treatment of schizophrenia
Józef Muszyński, Agnieszka Bienert, Rasha Wafaie Mahmoud Elsorady, et al.
Pharmacological Reports (2025)
Closed Access
Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders
Savelii R. Kuvarzin, Ilya Sukhanov, Kirill Onokhin, et al.
Biomedicines (2023) Vol. 11, Iss. 7, pp. 1977-1977
Open Access | Times Cited: 11
Structure-Based Design of Novel G-Protein-Coupled Receptor TAAR1 Agonists as Potential Antipsychotic Drug Candidates
Zhenzhen Zhou, Weifeng Zhang, Fabao Zhao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 5, pp. 4234-4249
Closed Access | Times Cited: 3
2-Heteroarylethylamines in medicinal chemistry: a review of 2-phenethylamine satellite chemical space
Carlos T. Nieto, Alejandro Manchado, Ángel García-González, et al.
Beilstein Journal of Organic Chemistry (2024) Vol. 20, pp. 1880-1893
Open Access | Times Cited: 3
The trace amine-associated receptor 1 agonists – non-dopaminergic antipsychotics or covert modulators of D2 receptors?
Gavin P. Reynolds
Journal of Psychopharmacology (2024) Vol. 38, Iss. 6, pp. 503-506
Open Access | Times Cited: 2
Unlocking the secrets of trace amine-associated receptor 1 agonists: new horizon in neuropsychiatric treatment
Britto Shajan, Tarun Bastiampillai, Shane D. Hellyer, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 2
New directions in psychiatric drug development: promising therapeutics in the pipeline
Linda S. Brady, Sarah H. Lisanby, Joshua A. Gordon
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 8, pp. 835-850
Closed Access | Times Cited: 6
Trace Amine-Associated Receptors and Monoamine-Mediated Regulation of Insulin Secretion in Pancreatic Islets
Anastasia N. Vaganova, Taisiia S. Shemyakova, Карина Владимировна Ленская, et al.
Biomolecules (2023) Vol. 13, Iss. 11, pp. 1618-1618
Open Access | Times Cited: 4
Discovery of Guanfacine as a Novel TAAR1 Agonist: A Combination Strategy through Molecular Modeling Studies and Biological Assays
Elena Cichero, Valeria Francesconi, Beatrice Casini, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 11, pp. 1632-1632
Open Access | Times Cited: 4
The New Horizon of Antipsychotics beyond the Classic Dopaminergic Hypothesis—The Case of the Xanomeline-Trospium Combination: A Systematic Review
Octavian Vasiliu, Beatrice Budeanu, Mihai Stefan Catanescu
(2024)
Open Access | Times Cited: 1
Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review.
Waguih William IsHak, Ashley N. D. Meyer, Luiza Freire, et al.
PubMed (2024) Vol. 21, Iss. 7-9, pp. 27-47
Closed Access | Times Cited: 1
Pharmacologie et mode d’action des antipsychotiques
N. Franck, F. Fromager, F. Thibaut
Encyclopédie médico-chirurgicale. Psychiatrie (2015) Vol. 31, Iss. 1, pp. 1-17
Closed Access | Times Cited: 6
Assessment of Innovative Pharmacological Targets in Schizophrenia
Teresa Reynolds de Sousa, M. Ribeiro, Filipa Novais
Current Treatment Options in Psychiatry (2024) Vol. 11, Iss. 3, pp. 203-217
Open Access
Page 1 - Next Page

Scroll to top